Histone deacetylases (HDAC) in physiological and pathological bone remodelling.

Area of Science:

• Biochemistry
• Molecular Biology
• Epigenetics

Background:

• Histone deacetylases (HDACs) regulate gene expression epigenetically.
• HDAC inhibitors (HDACi) are clinically used for malignancies.
• HDACs are increasingly recognized for roles in non-malignant conditions like bone loss.

Purpose of the Study:

• To review the roles of individual HDAC isozymes in bone cells.
• To examine the effects of HDAC inhibitors on bone remodeling in pathological bone loss.
• To highlight the potential of isozyme-specific HDACi for treating bone diseases.

Main Methods:

• Literature review of HDAC isozyme functions.
• Analysis of HDAC inhibitor effects on osteoblasts, osteoclasts, and osteocytes.
• Examination of HDAC roles in periodontitis, rheumatoid arthritis, and myeloma bone disease.

Main Results:

• HDACs play critical roles in regulating bone cell function and bone remodeling.
• HDAC inhibitors demonstrate potential in preclinical models of bone loss.
• Isozyme-specific HDAC inhibitors are crucial for understanding individual HDAC functions and developing targeted therapies.

Conclusions:

• Targeting specific HDAC isozymes holds promise for treating pathological bone loss.
• Isozyme-specific HDAC inhibitors may offer improved efficacy and reduced side effects compared to broad-spectrum inhibitors.
• Further research into individual HDAC functions is essential for advancing bone disease therapeutics.